Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8266 to 8280 of 9128 results

  1. Accident and emergency departments

    Discontinued Reference number: GID-SGWAVE0762

    Safe staffing guideline
    Discontinued

  2. Lanreotide (subcutaneous injection) for treating unresectable locally advanced or metastatic, non-progressive gastroenteropancreatic tumours [ID961]

    Discontinued Reference number: GID-TA10026

    Technology appraisal guidance
    Discontinued

  3. Workplace health - older employees

    Discontinued Reference number: GID-PHG59

    NICE guideline
    Discontinued

  4. Maternal health: promoting maternal health through community based strategies

    Discontinued Reference number: GID-QS10016

    Quality standard
    Discontinued

  5. Community nursing care settings

    Discontinued Reference number: GID-SGWAVE0700

    Safe staffing guideline
    Discontinued

  6. Inpatient mental health settings

    Discontinued Reference number: GID-SGWAVE0701

    Safe staffing guideline
    Discontinued

  7. Belatacept for the prevention of organ rejection in kidney transplantation [ID87]

    Discontinued Reference number: GID-TAG239

    Technology appraisal guidance
    Discontinued

  8. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued Reference number: GID-TAG330

    Technology appraisal guidance
    Discontinued

  9. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued Reference number: GID-TAG337

    Technology appraisal guidance
    Discontinued

  10. Prasterone for the treatment of systemic lupus erythematosus [ID392]

    Discontinued Reference number: GID-TAG373

    Technology appraisal guidance
    Discontinued

  11. Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]

    Discontinued Reference number: GID-TA10634

    Technology appraisal guidance
    Discontinued

  12. Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

    Discontinued Reference number: GID-TA10637

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued Reference number: GID-TA10697

    Technology appraisal guidance
    Discontinued

  14. Retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

    Discontinued Reference number: GID-TA10698

    Technology appraisal guidance
    Discontinued

  15. Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264]

    Discontinued Reference number: GID-TA10365

    Technology appraisal guidance
    Discontinued